Polyrizon Ltd. (PLRZ) Research

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

Market snapshot

Symbol
PLRZ
Price
$13.42
Day change
+1.44%
Market cap
$15.0M
P/E ratio
-5.24x
52-week range
2.88-18.2
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AIM ImmunoTech Inc. (AIM)
  • Cyclerion Therapeutics, Inc. (CYCN)
  • Pasithea Therapeutics Corp. (KTTA)
  • NovaBay Pharmaceuticals, Inc. (NBY)
  • PharmaCyte Biotech, Inc. (PMCB)
  • Quoin Pharmaceuticals, Ltd. (QNRX)
  • Radiopharm Theranostics Limited (RADX)
  • Alaunos Therapeutics, Inc. (TCRT)

Recent insider activity

  • Izraeli Tomer — S-Sale (500 shares) on 2026-03-31
  • Carmel Liron — S-Sale (942 shares) on 2026-03-31
  • Adler Oz — S-Sale (3292 shares) on 2026-03-31
  • Carmel Liron — S-Sale (100 shares) on 2026-03-30
  • Izraeli Tomer — S-Sale (3900 shares) on 2026-03-30

Open Polyrizon Ltd. (PLRZ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.